
Efficacy, safety, and pharmacokinetics of a high-purity plasma-derived factor X (pdFX) concentrate in the prophylaxis of bleeding episodes in children <12 years with moderate to severe congenital factor X deficiency (FXD)
AWARDED/PRESENTED: 2017
GRANT/PROGRAM:
Bleeding Disorders Conference
Clinical Research/Clinical Trials